The pathogenesis of coronary artery disease and the acute coronary syndromes

New England Journal of Medicine

Volumn 326, Issue 5, 1992, Pages 310-318

  Epstein, Franklin H ^a   Fuster, Valentin ^b   Badimon, Lina ^b   Badimon, Juan J ^b   Chesebro, James H ^c  

^a Harvard Medical School ^*

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; COLESTIPOL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PROTEIN C; SEROTONIN ANTAGONIST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS; VASOCONSTRICTION;

CORONARY DISEASE; CORONARY THROMBOSIS; CORONARY VESSELS; HUMAN; SYNDROME;

EID: 0026541706     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199201303260506     Document Type: Review

References (102)

1. Badimon L., Badimon J.J., Turitto V.T., Vallabhajosula S., Fuster V. Platelet thrombus formation on collagen type I: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation 1988; 78:1431-1442
2. Badimon L., Badimon J.J. Mechanism of arterial thrombosis in nonparallel streamlines: platelet thrombi grow at the apex of stenotic severely injured vessel wall: experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
3. Lassila R., Badimon J.J., Vallabhajosula S., Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: effects of different stenosis on thrombus growth. Arteriosclerosis 1990; 10:306-315
4. Capone G., Wolf N.M., Meyer B., Meister S.G. Frequency of intracoronary filling defects by angiography in unstable angina pectoris at rest. Am J Cardiol 1985; 56:403-406
5. Hirsh P.D., Hillis L.D., Campbell W.B., Firth B.G., Willerson J.T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304:685-691
6. Simionescu N., Mora R., Vasile E., Lupu F., Filip D.A., Simionescu M. Prelesional modifications of the vessel wall in hyperlipidemic atherogenesis: extracellular accumulation of modified and reassembled lipoproteins. Ann N Y Acad Sci 1990; 598:1-16.
7. Fitzgerald D.J., Roy L., Catella F., FitzGerald G.A. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983-989
8. van den Berg E.K., Schmitz J.M., Benedict C.R., Malloy C.R., Willerson J.T., Dehmer G.J. Transcardiac serotonin concentration is increased in selected patients with limiting angina complex coronary lesion morphology. Circulation 1989; 79:116-124
9. Willerson J.T., Yao S.-K., McNatt J., et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A 1991; 88:10624-8.
10. Gold H., Yasuda T., Jang I.-K., et al. Animal models for arterial thrombolysis and prevention of reocclusion: erythrocyte-rich versus platelet-rich thrombus. Circulation 1991; 83:Suppl:IV-26-IV-40.
11. Davies S.W., Marchant B., Lyons J.P., et al. Coronary lesion morphology in acute myocardial infarction: demonstration of early remodeling after streptokinase treatment. J Am Coll Cardiol 1990; 16:1079-1086
12. Gulba D.C., Bartheis M., Westhoff-Bleck M., et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation 1991; 83:937-944
13. Hackett D., Davies G., Chierchia S., Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilatory therapy. N Engl J Med 1987; 317:1055-1059
14. Badimon L., Badimon J.J., Lassila R., Merino A., Chesebro J.H., Fuster V. Rethrombosis on an evolving thrombus is mediated by thrombus-bound thrombin that is not inhibited by systemic heparin. Thromb Haemost 1991; 65:Suppl:321.
15. Fitzgerald D.J., FitzGerald G.A. Role of thrombin and THROMBOXANE A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1989; 86:7585-7589
16. Francis C.W., Markham R.E. Jr., Barlow G.H., Florack T.M., Dobrzynski D.M., Marder V.J. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102:220-230
17. Owen J., Friedman K.D., Grossman B.A., Wilkins C., Berke A.D., Powers E.R. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72:616-620
18. Fitzgerald D.J., Catella F., Roy L., FitzGerald G.A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77:142-150
19. Eisenberg P.R., Sherman L.A., Jaffe A.S. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10:527-529
20. Badimon L., Lassila R., Badimon J., Fuster V. An acute surge of epinephrine stimulates platelet deposition to severely damaged vascular wall. J Am Coll Cardiol 1990; 15:Suppl:181A.
21. Grignani G., Soffiantino F., Zuccheila M., et al. Platelet activation by emotional stress in patients with coronary artery disease. Circulation 1991; 83: Suppl II:II-128-II-136.
22. Yeung AC, Vekshtein V.I., Krantz D.S., et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991; 325:1551-1556
23. Muller J.E., Stone P.H., Turi Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313:1315-1322
24. Tofler G.H., Brezinski D., Schafer A.I., et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316:1514-1518
25. Willich S.N., Linderer T., Wegscheider K., Leizorovicz A., Alamercery I., Schroder R. Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior β-adrenergic blockade. Circulation 1989; 80:853-858
26. Fuster V., Chesebro J.H., Frye R.L., Elveback L.R. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation 1981; 63:546-551
27. Winniford M.D., Wheelan K.R., Kremers M.S., et al. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation 1986; 73:662-667
28. Cullen J.W., McKenna J.W., Massey M.M. International control of smoking and the US experience. Chest 1986; 89:Suppl:206S-218S.
29. Buhler F.R., Vesanen K., Watters J.T., Bolli P. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. Am Heart J 1988; 115:282-288
30. Paul O. Background of the prevention of cardiovascular disease. II. Arteriosclerosis, hypertension, and selected risk factors. Circulation 1989; 80: 206-14.
31. Hunt B.J. The relation between abnormal hemostatic function and the progression of coronary disease. Curr Opin Cardiol 1990; 5:758-765
32. Badimon J.J., Badimon L., Turitto V.T., Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels: in vivo study in the rabbit model. Arterioscler Thromb 1991; 11:395-402.
33. Boers G.H.J., Smals A.G.H., Trijbels F.J.M., et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:709-715
34. Genest J.J. Jr., McNamara J.R., Upson B., et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11:1129-1136
35. Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocystine-induced atherosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741
36. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case–control study in a general population sample of middle aged men. BMJ 1990; 301:1248-1251
37. Dahlen G.H., Guiyton J.R., Attar M., Farmer J.A., Kautz J.A., Gotto A.M. Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758-765
38. Seed M., Hoppichler F., Reaveley D., et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease patients with familial hypercholesterolemia. N Engl J Med 1990; 322:1494-1499
39. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 30:132-137
40. Frank S.L., Klisak I., Sparkes R.S., et al. The apoprotein(a) gene resides on human chromosome 6q26–27 in close proximity to the homologous gene for plasminogen. Hum Genet 1988; 79:352-356
41. Karàdi I., Kostner G.M., Gries A., Nimpf J., Romics L., Malle E. Lipoprotein(a) and plasminogen are immunochemically related. Biochim Biophys Acta 1988; 960:91-97
42. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339:303-305
43. Harpel P.L., Gordon B.R., Parker T.S. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 1989; 56:3847-3851
44. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10:672-679
45. Olofsson B.O., Dahlen G., Nilsson T.K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10:77-82.
46. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
47. Aznar J., Estelles A., Tormo G., et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59:535-541
48. Oseroff A., Krishnamurti C., Hassett A., Tang D., Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1990; 113:88-93.
49. Meade T.W., North W.R.S., Chakrabarti R., et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-4.
50. Kannel W.B., D#x0027;Agostino R.B., Belanger A.J. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113:1006-1010
51. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-505
52. McGill D.A., Ardlie N.G. The relationship between blood fibrinogen level and coronary artery disease. Coronary Artery Dis 1990; 1:557-566
53. Rosengren A., Wilhelmsen L., Welin L., Tsipogianni A., Teger-Nilsson A.C., Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. BMJ 1990; 300:634-638
54. Scarabin P.Y., Bonothon-Kopp C., Bara L., Malmejac A., Guize L., Samama M. Factor VII activation and menopausal status. Thromb Res 1990; 57:227-234
55. Maseri A., L#x0027;Abbate A., Baroldi G., et al. Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of “preinfarction” angina. N Engl J Med 1978; 299:1271-1277
56. Lam J.Y.T., Chesebro J.H., Steele P.M., Badimon L., Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation 1987; 75:243-248
57. Vanhoutte P.M., Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989; 80:1-9.
58. Fischell T.A., Derby G., Tse T.M., Stadius M.L. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. Circulation 1988; 78:1323-1324
59. el-Tamimi H., Davies G.J., Hackett D., et al. Abnormal vasomotor changes early after coronary angioplasty. Circulation 1991; 84:1198-1202
60. Araki H., Nishi K., Jougasaki M. Effects of thrombosis on vascular tone in rat mesenteric arteries with endothelium in vivo. Circ Res 1990; 67:312-318
61. Vane J.R., Änggåard E.E., Botting R.M. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323:27-36.
62. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-665
63. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 299: 373-6.
64. Furlong B., Henderson A.H., Lewis M.J., Smith J.A. Endothelium-derived relaxant factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987; 90:687-692
65. Palmer R.M.J., Ashton D.S., Moneada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666
66. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415
67. Endothelins. Lancet 1991; 337:79-81.
68. Toyo-oka T., Aizawa T., Suzuki N., et al. Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation 1991; 83:476-483
69. Yang Z.H., Richard V., von Segesser L., et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: anew mechanism of vasospasm? Circulation 1990; 82:188-195
70. Miyauchi T., Yanagisawa M., Tomizawa T., et al. Increased plasma concentration of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989; 2:53-54
71. Komuro I., Kurihara H., Sugiyama T., Yoshizumi M., Takaku F., Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238:249-252
72. McLenachan J.M., Vita J., Fish R.D., et al. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation 1990; 82: 1169-73.
73. Cohen R.A., Zitnay K.M., Haudenschild C.C., Cunningham L.D. Loss of selective endothelial cell vasoactive stimuli in hypercholesterolemia in pig coronary arteries. Circ Res 1988; 63:903-910
74. Osborne J.A., Lento P.H., Siegfried M.R., Stahl G.L., Fusman B., Lefer A.M. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest 1989; 83:465-473
75. McLenachan J.M., Williams J.K., Fish R.D., Ganz P., Selwyn A.P. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991; 84:1273-1278
76. Zeiher A.M., Drexler H., Wollschlager H., Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83:391-401.
77. Chester A.H., O#x0027;Neill G.S., Moneada S., Tadjkarimi S., Yacoub M.H. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336:897-900.
78. Willerson J.T., Hillis L.D., Winniford M., Buja L.M. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol 1986; 8:245-250
79. Braunwald E. Unstable angina: a classification. Circulation 1989; 80:410-414
80. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364
81. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255
82. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245
83. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298
84. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946-955
85. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashen-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240
86. [Erratum, JAMA 1988; 259:2698.]
87. Blankenhorn D.H., Johnson R.L., Mack W.J., el Zein H.A., Vailas L.I. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990; 263:1646-1652
88. Ornish D., Brown S.E., Scherwitz L.W., et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129-133
89. Kane J.P., Malloy M.K.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-3012
90. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79:8-15.
91. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700-1707
92. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373-381
93. Reichl D., Miller N.E. Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 1989; 9:785-797
94. Badimon J.J., Badimon L., Galvez A., Dische R., Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989; 60:455-461
95. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1241
96. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353:265-267
97. Antiplatelet Trialists#x0027; Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296:320-331
98. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360
99. Hennekens C.H., Buring J.E., Sandercock P., Collins R., Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80:749-756
100. Stein B., Fuster V. Clinical pharmacology of platelet inhibitors. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: W.B. Saunders, 1992: 99-120.
101. Smith P. Antithrombotic therapy in the chronic phase of myocardial infarction. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: W.B. Saunders, 1992: 343-62.
102. Verstraete M. Novelties in antithrombotic and thrombolytic therapy: a latest update. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: W.B. Saunders, 1992: 529-44.